| 1 |
18780206 | Dosing time-dependent effect of raloxifene on plasma fibrinogen concentration in ovariectomized rats. | 2008 Sep |
2 |
| 2 |
16784972 | Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia. | 2006 Jul |
1 |
| 3 |
17162709 | Effects of intranasal 17beta-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: a randomized, placebo-controlled clinical trial. | 2006 Dec |
2 |
| 4 |
15614199 | Raloxifene does not prevent fibrinogen oxidation in vitro. | 2005 Jan |
3 |
| 5 |
15804733 | Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. | 2005 Mar |
1 |
| 6 |
15967604 | Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1. | 2005 Oct 16 |
1 |
| 7 |
16202731 | The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women. | 2005 Oct |
2 |
| 8 |
15006256 | Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study. | 2003 Dec |
1 |
| 9 |
11770189 | Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study. | 2001 Dec |
3 |
| 10 |
10591680 | Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. | 1999 Dec |
2 |